MedTrace Logo

A Study of BGM0504 in Overweight or Obese Participants

NCT06920056 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2025-09-09

No results posted yet for this study

Summary

The purpose of the study is to evaluate the influence of BGM0504 injection on gastric emptying and Pharmacokinetics of metformin and warfarin in overweight or obese participants

Conditions

  • Overweight or Obese

Interventions

DRUG

Paracetamol

oral, postprandial

DRUG

Metformin Hydrochloride

Oral , Fasting

DRUG

Warfarin

Oral , Fasting

DRUG

BGM0504

Administered SC

Sponsors & Collaborators

  • BrightGene Bio-Medical Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-24
Primary Completion
2025-07-25
Completion
2025-07-25
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06920056 on ClinicalTrials.gov